NRG Therapeutics launches brain-tracking study for new neurodegenerative drug
NRG Therapeutics has started a PET imaging biodistribution trial (NRG5051-102) of its lead clinical asset NRG5051. The company says it has successfully radiolabelled NRG5051 and initiated PET scans in healthy volunteer participants in London to demonstrate central nervous system penetration and to i
<p>NRG Therapeutics has started a PET imaging biodistribution trial (NRG5051-102) of its lead clinical asset NRG5051. The company says it has successfully radiolabelled NRG5051 and initiated PET scans in healthy volunteer participants in London to demonstrate central nervous system penetration and to i</p>